Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 2:54 PM ET on Feb 12, 2016
Last Price Change Open Day High 52-Week High
14.91
0.31  up   (2.123%) 14.75 14.94 120.96
Volume Previous Close Day Low 52-Week Low
198,108 14.60 13.85 12.61

View all »   RSSRecent Releases

Jan 13, 2016
Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study

Jan 12, 2016
Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy